The twin effects of rapid development and increasing complexity in cancer research can be seen as both a good and a bad thing because while both negative and positive results might be a helpful window into where current research might be (or should be currently headed), it also means that for industry project teams, clinical development plans are much more challenging to put together.

Rising or setting of key targets and molecules?

This is also a reflection of the current state of research in immuno-oncology – things are much more complicated than many people realised even just a decade ago – as we slowly peel off the layers of the onion to reveal yet more layers and unknowns.

In short, we still don’t know what we don’t know on many key issues, never mind how various cells might interact and communicate in both health and disease.

With this in mind, I wanted to take a moment and offer a top-line review of six key areas to watch out for as we head towards the Fall conference season…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by